JP2020535119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535119A5 JP2020535119A5 JP2020513721A JP2020513721A JP2020535119A5 JP 2020535119 A5 JP2020535119 A5 JP 2020535119A5 JP 2020513721 A JP2020513721 A JP 2020513721A JP 2020513721 A JP2020513721 A JP 2020513721A JP 2020535119 A5 JP2020535119 A5 JP 2020535119A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- determined
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 41
- 230000035772 mutation Effects 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 239000003550 marker Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 20
- 230000014509 gene expression Effects 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 8
- 201000002528 pancreatic cancer Diseases 0.000 claims 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 6
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- -1 CD86 Proteins 0.000 claims 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 5
- 102100033499 Interleukin-34 Human genes 0.000 claims 5
- 101710181549 Interleukin-34 Proteins 0.000 claims 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 4
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 4
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 4
- 102100030386 Granzyme A Human genes 0.000 claims 4
- 102100038393 Granzyme H Human genes 0.000 claims 4
- 102100022087 Granzyme M Human genes 0.000 claims 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 4
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 4
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 4
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 4
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 4
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims 4
- 101000900697 Homo sapiens Granzyme M Proteins 0.000 claims 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 4
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 claims 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 4
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 claims 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 4
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 claims 4
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 claims 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 4
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 4
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 102100023370 Protein NKG7 Human genes 0.000 claims 4
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 4
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 4
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 claims 4
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 claims 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 4
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 210000001616 monocyte Anatomy 0.000 claims 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 102100021186 Granulysin Human genes 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 3
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 3
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 3
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 3
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims 3
- 102100028467 Perforin-1 Human genes 0.000 claims 3
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims 3
- 102100030766 Apolipoprotein L3 Human genes 0.000 claims 2
- 102100026658 Cathepsin W Human genes 0.000 claims 2
- 101000793443 Homo sapiens Apolipoprotein L3 Proteins 0.000 claims 2
- 101000910988 Homo sapiens Cathepsin W Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 108091092878 Microsatellite Proteins 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 239000002771 cell marker Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000011272 standard treatment Methods 0.000 claims 2
- 238000011222 transcriptome analysis Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060052A JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558161P | 2017-09-13 | 2017-09-13 | |
| US62/558,161 | 2017-09-13 | ||
| US201762580154P | 2017-11-01 | 2017-11-01 | |
| US62/580,154 | 2017-11-01 | ||
| US201762581962P | 2017-11-06 | 2017-11-06 | |
| US62/581,962 | 2017-11-06 | ||
| US201862671887P | 2018-05-15 | 2018-05-15 | |
| US62/671,887 | 2018-05-15 | ||
| US201862679612P | 2018-06-01 | 2018-06-01 | |
| US62/679,612 | 2018-06-01 | ||
| PCT/US2018/050711 WO2019055537A1 (en) | 2017-09-13 | 2018-09-12 | ANTI-CSF1R AND ANTI-PD -1 ANTIBODY POLYTHERAPY FOR PANCREATIC CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060052A Division JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535119A JP2020535119A (ja) | 2020-12-03 |
| JP2020535119A5 true JP2020535119A5 (enExample) | 2021-10-21 |
Family
ID=63708492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513721A Pending JP2020535119A (ja) | 2017-09-13 | 2018-09-12 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法 |
| JP2023060052A Pending JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060052A Pending JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11421034B2 (enExample) |
| EP (1) | EP3681535A1 (enExample) |
| JP (2) | JP2020535119A (enExample) |
| KR (1) | KR20200051024A (enExample) |
| CN (1) | CN111479586A (enExample) |
| AU (1) | AU2018334171A1 (enExample) |
| BR (1) | BR112020004879A2 (enExample) |
| CA (1) | CA3073531A1 (enExample) |
| IL (1) | IL272669A (enExample) |
| MX (1) | MX2020002301A (enExample) |
| SG (1) | SG11202001606XA (enExample) |
| WO (1) | WO2019055537A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022534982A (ja) * | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2021022256A1 (en) * | 2019-08-01 | 2021-02-04 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| KR20210100457A (ko) * | 2020-02-06 | 2021-08-17 | 아주대학교산학협력단 | 케모카인 억제제, 콜로니 자극 인자 억제제 및 면역항암제를 포함하는 암의 예방 또는 치료용 조성물 및 병용 요법 |
| US20230184771A1 (en) * | 2020-04-21 | 2023-06-15 | Board Of Regents, The University Of Texas System | Methods for treating bladder cancer |
| EP4112746A1 (en) * | 2021-07-02 | 2023-01-04 | STRATIFYER Molecular Pathology GmbH | Method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003687A1 (en) | 1987-10-23 | 1989-05-05 | Genetics Institute, Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| JPH08507916A (ja) | 1992-06-09 | 1996-08-27 | カイロン コーポレイション | Ｍ−ｃｓｆの結晶化 |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| EP1125584A4 (en) | 1998-10-30 | 2005-01-12 | Takeda Chemical Industries Ltd | PREPARATIONS CONTAINING BETACELLULIN PROTEIN |
| ATE240744T1 (de) | 1999-10-28 | 2003-06-15 | Hofbauer Reinhold | Verwendung von csf-1-inhibitoren |
| AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| JP2007524671A (ja) | 2004-01-21 | 2007-08-30 | カイロン コーポレイション | Ｍ−ｃｓｆムテインおよびその使用 |
| US20060286102A1 (en) | 2004-05-14 | 2006-12-21 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| US20070264277A1 (en) | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR20080082628A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 수용체 및 리간드 이소형태의 제조 방법 |
| WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| AU2006342119B8 (en) | 2005-12-22 | 2013-05-09 | Novartis Ag | Soluble human M-CSF receptor and uses thereof |
| RU2470665C2 (ru) | 2006-01-05 | 2012-12-27 | Новартис Аг | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом |
| WO2008060610A2 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| WO2008150383A1 (en) | 2007-05-30 | 2008-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | Csf-1r mutants |
| TWI595005B (zh) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| EP2215482A2 (en) | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| WO2009075344A1 (ja) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用 |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| MX2010009894A (es) | 2008-03-14 | 2011-02-22 | Transgene Sa | Anticuerpo contra csf-1r. |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| EP2307050A4 (en) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| PL2949670T3 (pl) | 2009-12-10 | 2019-07-31 | F. Hoffmann-La Roche Ag | Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie |
| US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| AU2011248083B2 (en) | 2010-05-04 | 2015-09-10 | Five Prime Therapeutics, Inc. | Antibodies that bind CSF1R |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| WO2012082573A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| JP6005751B2 (ja) | 2011-10-21 | 2016-10-12 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | マクロファージの活性化の調節 |
| WO2013057290A1 (en) | 2011-10-21 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP2890398A4 (en) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| CA2938566A1 (en) * | 2014-02-04 | 2015-08-13 | Incyte Corporation | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| US9765147B2 (en) * | 2014-10-29 | 2017-09-19 | Five Prime Therapeutics, Inc. | Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| CA3038712A1 (en) * | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| IL271888B2 (en) * | 2017-07-21 | 2024-09-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
-
2018
- 2018-09-12 MX MX2020002301A patent/MX2020002301A/es unknown
- 2018-09-12 EP EP18779538.0A patent/EP3681535A1/en not_active Withdrawn
- 2018-09-12 KR KR1020207010187A patent/KR20200051024A/ko not_active Ceased
- 2018-09-12 BR BR112020004879-8A patent/BR112020004879A2/pt not_active IP Right Cessation
- 2018-09-12 SG SG11202001606XA patent/SG11202001606XA/en unknown
- 2018-09-12 US US16/646,690 patent/US11421034B2/en active Active
- 2018-09-12 AU AU2018334171A patent/AU2018334171A1/en not_active Abandoned
- 2018-09-12 CN CN201880058749.8A patent/CN111479586A/zh active Pending
- 2018-09-12 CA CA3073531A patent/CA3073531A1/en active Pending
- 2018-09-12 JP JP2020513721A patent/JP2020535119A/ja active Pending
- 2018-09-12 WO PCT/US2018/050711 patent/WO2019055537A1/en not_active Ceased
-
2020
- 2020-02-13 IL IL272669A patent/IL272669A/en unknown
-
2022
- 2022-07-14 US US17/812,592 patent/US20230192870A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060052A patent/JP2023093514A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535119A5 (enExample) | ||
| US20210371932A1 (en) | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients | |
| Lecerf et al. | Immune gene expression in head and neck squamous cell carcinoma patients | |
| US11326211B2 (en) | Blood-based biomarkers of tumor sensitivity to PD-1 antagonists | |
| US20200347456A1 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
| KR102667593B1 (ko) | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 | |
| JP7197556B2 (ja) | がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法 | |
| US10711312B2 (en) | Methods for immunotherapy-based treatment and assessment of cancer | |
| Fasano et al. | Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer | |
| EP3606518A1 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
| KR20190112027A (ko) | 암 면역요법의 임상 효과 예측을 위한 면역 바이오마커 | |
| Davar et al. | Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial | |
| EP3887548A1 (en) | Method for predicting the response to cancer immunotherapy in cancer patients | |
| JP2017536842A5 (enExample) | ||
| US20210395374A1 (en) | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | |
| JP2020524149A5 (enExample) | ||
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| US10406218B2 (en) | Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of Mycobacterium tuberculosis | |
| WO2019147681A1 (en) | Methods for predicting tumor response to immunotherapy | |
| Yao et al. | Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment | |
| JP2022179694A (ja) | Ｋｒａｓバリアントがん患者の免疫ベースの処置 | |
| Aoki et al. | Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade | |
| Jang et al. | RNA N6‐Methyladenosine‐Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN‐γ Signaling in Gastric Cancer | |
| JP7739269B2 (ja) | がん療法のための複合バイオマーカー | |
| EP3976832A1 (en) | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |